065435-9048 US00

Under the Paperwork Reduction Act of 1995, no persons are	required to respond to a collection	of information unless it contains a valid OMB control number.
Substitute of form 1449/PTO		Complete if Known
REMATION DISCLOSURE STATEMENT BY	Application Number	10/534,825
APPLICANT	Filing Date	May 27, 2005
APPLICANT	First Name Inventor	David Thurston
- 1	Group Art Unit	N/A
A 2005 (use as many sheets as necessary)	Examiner Name	N/A

Attorney Docket Number

Sheet

of

Tre-miles	U.S.	PATENT DOCUMENTS	
Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
вк	3523941	Leimgruber et al	08/11/1970
1	3524849	Batcho et al.	08/18/1970
	4185016	Takanabe et al.	01/22/1980
	4239683	Takanabe et al.	12/16/1980
	4309437	Ueda et al.	01/05/1982
	5143854	Pirrung et al.	09/01/1992
	5545568	Ellman et al.	08/13/1996
	6747144	Thurston et al.	06/08/2004
	6562806	Thurston et al.	05/13/2003
	6608192	Thurston et al.	08/19/2003
	2003-0120069	Thurston et al.	06/26/2003
	2003-0195196	Thurston et al.	10/16/2003
	2004-0092736	Thurston et al.	05/13/2004
Φ	2004-0198722	Thurston et al.	10/07/2004

	FOREIGN PATENT DOCUMENTS					
Examiner Initials						
BK	wo	88/07378	Cancer Research Campaign Technology Ltd.	10/06/1988		

Examiner Signature	/Bruck Kifle/ (09/01/2006)	Date Considered	09/01/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

Subst	titute of form 1449/	РТО			Complete if Known	
INFORMAT	TION DISCLO	SURE STATE	MENT BY	Application Number	10/534,825	
APPLICANT				Filing Date	May 27, 2005	
				First Name Inventor	David Thurston	
				Group Art Unit	N/A	
(use as many sheets as necessary)			<u> </u>	Examiner Name	N/A	
Sheet	2	of	2	Attorney Docket Number	065435-9048 US00	•

	U.S. PATENT DOCUMENTS					
Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document		

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
BK	wo	89/10140	Cancer Research Campaign Technology Ltd.	11/02/1989		
	wo	92/19620	Centre National de la Recherche Scientifique	11/12/1992		
	wo	93/08288	Cancer Research Campaign Technology Ltd.	04/29/1993		
	wo	93/18045	Cancer Research Campaign Technology Ltd.	09/16/1993		
	wo	97/01560	Pharmacopeia, Inc.	01/16/1997		
	wo	00/12506	The University of Portsmouth Higher Education Group	03/09/2000		
	wo	00/12507	The University of Portsmouth Higher Education Corp.	03/09/2000		
	EP	0239400A2	Winter, G.P.	09/30/1987		
	FR	2027356	Fujisawa Pharmaceutical Co. Ltd.	12/29/1969		
	FR	2586683	Centre National de la Recherche Scientifique	03/06/1987		
	GB	1299198	Fujisawa Pharmaceutical Co. Ltd.	12/06/1972		
	JР	53-82792	Microbiological Chemical Research	07/21/1978		
	JP	57131791	Fujisawa Pharmaceutical Co. Ltd.	08/14/1982		
V	JР	58180487 A	Kyowa Hakko Kogyo Co. Ltd.	10/21/1983		

Q:\CLIENT\065435\9048\B0620173.1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number. Complete if Known Substitute for form 1449B/PTO Application Number 10/534,825 TROPMATION DISCLOSURE Filing Date May 27, 2005 TEMENT BY APPLICANT First Named Inventor **David Thurston** Group Art Unit N/A DEC 1 9 20 use as many sheets as necessary) Examiner Name N/A

Sheet of g Attorney Docket Number 065435-9048 US00 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published. BK ALBERICIO, F. et al., "NPE-Resin, A New Approach to the Solid-Phase Synthesis of Protected Peptides and Oligonucleotides II. Synthesis of Protected Peptides 1.2," Tetrahedron Letters, 32:1515-1518 (1991)

BK	ALBERICIO, F. et al., "NPE-Resin, A New Approach to the Solid-Phase Synthesis of Protected Peptides and Oligonucleotides II. Synthesis of Protected Peptides ^{1,2} ," Tetrahedron Letters, 32:1515-1518 (1991)
	ALBERICIO, F. et al., "NPE-resin, a new approach to the solid-phase synthesis of protected peptides and oligonucleotides," <i>Peptides</i> 1990, Proc. 21.sub.st Eur. Pept. Symp., 134-136 (1990)
	ALTHIUS, T. H. and HESS, H. J., "Synthesis and Identification of the Major Metabolites of Prazosin Formed in Dog and Rat," J. Medicinal Chem., 20(1), 146-148 (1977)
	ARIMA et al., "Studies on Tomaymycin, a New Antibiotic. I. Isolation and Properties of Tomaymycin," J. Antibiotics, 25, 437-444 (1972)
	ARISTOFF, J and JOHNSON, P., "Synthesis of CBI-PDE-I-Dimer, the Benzannelated Analogue of CC-1065," J. Org. Chem., 57, 6234-6239 (1992)
	BAGSHAWE et al., "Antibody-Enzyme Conjugates Can Generate Cytotoxic Drugs from Inactive Precursors at Tumor Sites," Antibody, Immunoconjugates, and Radiopharmaceuticals, 4, 915-922 (1991)
	BARALDI, P.G. et al., "Design, synthesis and biological activity of a pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid," Bioorganic & Medicinal Chemistry Letters, vol. 8, No. 21, 3019-3024 (1998)
	BARALDI, P.G. et al., "Synthesis, in Vitro Antiproliferative Activity, and DNA-Binding Properties of Hybrid Molecules Containing Pyrrolo[2,1-c][1,4]benzodiazepine and Minor-Groove-Binding Oligopyrrole Carriers," J. Med. Chem., 42, 5131-5141 (1999)
	BAYLEY, H. et al., "Photoactivatable drugs," TIPS, 8, 138-143 (1987)
	BERRY, J. M. et al., "Solid-phase synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines," Tetrahedron Letters, 41, 6171-6174 (2000)
	BI, Y. et al., "Building blocks for peptide and carbamate libraries", Bioorganic & Medicinal Chemistry Letters, vo 6, No. 19, 2299-2300 (1996)
	BI, Y., et al., "Building blocks for peptide and carbamate libraries," Chemical Abstracts, vol. 125, No. 23, 1013 (1996)
	BOGER et al., "CC-1065 and the Duocarmycins: Synthetic Studies," Chem. Rev., 97, 787-828 (1997)
	BOSE et al., "New Approaches to Pyrrolo[2,1-c][1,4]benzodiazepines: Synthesis, DNA-binding and cytotoxicity of DC-81," <i>Tetrahedron</i> , 48, 751-758 (1992)
	BOSE, D.S. et al., "Rational Design of a Highly Efficient Irreversible DNA Interstrand Cross-Linking Agent Base on the Pyrrolobenzodiazepine Ring System," J. Am. Chem. Soc., 114, 4939-4941 (1992)
Ψ	BRIDGES, R.J. et al., "Conformationally Defined Neurotransmitter Analogues. Selective Inhibition of Glutamate Uptake by One Pyrrolidine-2,4-dicarboxylate Diastereomer," J. Med. Chem., 34, 717-725 (1991)

Examiner		Date	
Signature	/Bruck Kifle/ (09/01/2006)	Considered	09/01/2006
	<u> </u>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Under the Pap	erwork Reduction	on Act of 1995, n	o persons are required to respond	to a collection of information unless it contains a valid OMB num	ıber.
Substitute for form 1449B/PTO			Complete if Known			
	INFORMATION DISCLOSURE		Application Number	10/534,825		
INFOR	MATIO	N DISCL	OSURE	Filing Date	May 27, 2005	
STATE	EMENT E	3Y APPL	ICANT	First Named Inventor	David Thurston	
				Group Art Unit	N/A	
ı.	(use as many she	ets as necessary)	Examiner Name	N/A	
Sheet	2	of	7	Attorney Docket Number	065435-9048 TISOO	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
BK	BROWN, S.C. et al., "NMR Solution Structure of a Peptide Nucleic Acid Complexed with RNA," Science, 265, 777-780 (1994)
	BUNDGAARD, H., "Design and Application of Prodrugs," A Textbook of Drug Design and Development, eds Krogsgaard-Lassen, P., and Bundgaard, H., Harwood Academic Press, 113-135 (1991)
	BURGESS, K. et al., "Solid Phase Synthesis of Oligoureas", J.Ame. Chem. Soc., 119: 1556-1564 (1997)
	BURGESS, K et al., "Solid Phase Synthesis of Unnatural Biopolymers Containing Repeating Urea Units," Agnew Chem. Int. Ed. Engl, 34, No. 8:907-909 (1995)
	CARRUTH, J.A.S., "Clinical applications for photodynamic therapy," J. Photochem Photobiol., 9, 396-397 (1991)
	CHO, C Y et al., "An Unnatural Biopolymer", Science, 261: 1303-1305 (1993)
	COURTNEY, S. M. et al., "A new convenient procedure for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines", Tetrahedron Letters, vol. 34, No. 33, 5327-28 (1993)
	CULVER et al., "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors," Science, 256, 1550-1552 (1992)
	DALTON, S. and TREISMAN, R, "Characterization of SAP-1, a Protein Recruited by Serum Response Factor to the c-fos Serum Response Element," Cell, 68, 597-612 (1992)
	DAMAYANTHI, Y., et al., "Design and synthesis of novel pyπolo {2,1-c][1,4] benzodiazepine-Lexitropsin Conjugates," J. Org. Chem., 64, 290-292 (1999)
	DANGLES, O. et al., "Selective Cleavage of the Allyl and Allyloxycarbonyl Groups through Palladium-Catalyzed Hydrostannolysis with Tributyltin Hydride. Application to the Selective Protection-Deprotection of Amino Acid Derivatives and in Peptide Synthesis," J. Org. Chem., 52, 4984-4993 (1987)
	DRESSMAN, B.A., et al., "Solid Phase Synthesis of Hydantoins Using a Carbamate Linker and a Novel Cyclization/Cleavage Step," Tetrahedron Letters, 37, 937-940 (1996)
	DROST, K.J. and CAVA, M.P., "A Photochemically Based Synthesis of the Benzannelated Analogue of the CC-1065 A Unit," J. Org. Chem., 56:2240-2244 (1991)
	EASHOO, M. et al., "Fibers from a Low Dielectric Constant Fluorinated Polyimide: Solution Spinning and Morphology Control," J. Polymer Science, 35:173-185 (1997)
	EDMAN, P. and BEGG, G., "A Protein Sequenator," Eur. J. Biochem., 1, 80-91 (1967)
V	EGHOLM, M et al., "Peptide Nucleic Acids (PNA). Oligonucleotide Analogues with an Achiral Peptide Backbone," J. Am. Chem. Soc., 114, 1895-1897 (1992)

Examiner	(D) 7153 / (00/05/0005)	Date	
Signature	/Bruck Kifle/ (09/01/2006)	Considered	09/01/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Under the Par	serwork Reduction	on Act of 1995, n	o persons are required to respond	to a collection of information unless it contains a valid OMB number.
Substitute for form 1449B/PTO			Complete if Known		
				Application Number	10/534,825
INFOR	MATIO	N DISCL	OSURE	Filing Date	May 27, 2005
STATI	STATEMENT BY APPLICANT			First Named Inventor	David Thurston
				Group Art Unit	N/A
(use as many sheets as necessary)				Examiner Name	N/A
Sheet	3	of		Attorney Docket Number	065435 0049 11500

T T	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.				
BK	EGHOLM, M et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <i>Nature</i> , 365, 566-568 (1993)				
	ENGLEHARDT et al., "Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1- deleted adenoviruses," Nature Genetics, 4, 27-34 (1993)				
	FARMER, J.D. et al., "DNA binding properties of a new class of linked anthramycin analogs,", Chemical Abstracts, Abstract No. 239940r, vol. 114, No. 25, 25 899-903 (1991)				
	FIGLIOZZI, G.M. et al., "Synthesis of N-substituted Glycine Peptoid Libraries," Methods in Enzymology, 267: 437-447 (1996)				
	FOLOPPE, M.P. et al., "DNA-binding properties of pyrrolo[2,1-c][1,4]benzodiazephine N10-C11 amidines," Eur. J. Med. Chem., 31, 407-410 (1996)				
	FUJISAWA PHARMACEUTICAL CO., LTD., Abstract No. 139983k, "Benzodiazepine derivatives", Chemical Abstracts, vol. 99, No. 17, 603 (1983)				
	FUJISAWA PHARMACEUTICAL CO., LTD., Abstract No. 72145x, "Benzodiazepine derivatives", Chemical Abstracts, vol. 98, No. 9, 638 (1983)				
	FUJISAWA PHARMACEUTICAL CO. LTD., "Benzodiazepine derivatives," SciFinder Scholar, 2-3 (2002)				
	FUKUYAMA, T. et al., "Total Synthesis of (+)-Porothramycin B," Tetrahedron Letters, vol. 34, 16, 2577-2580 (1993)				
	FURKA, A. et al., "General method for rapid synthesis of multicomponent peptide mixtures," Int. J. Peptide Protein Res., 37, 487-493 (1991)				
	GARCIA-ECHEVERRIA, C., "A Base Labile Handle for Solid Phase Organic Chemistry", Tetrahedron Letters, 38,52, 8933-8934 (1997)				
	GRANT, R. et al., Grant and Hackh's Chemical Dictionary, McGraw-Hill Book Company, 282 (1987)				
GREENE, T.W. and WUTS, P.G.M., Protective Groups in Organic Synthesis, John Wiley & S 315-345 (1991)					
	GREGSON, S. et al., "Synthesis of a novel C2/C2'-exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity," <i>Chemical Communications</i> , 797-798 (1999)				
	GREGSON, S.J. et al., "Design, Synthesis and Evaluation of a Novel Pyrrolobenzodiazepine DNA-Interactive Agent with Highly Efficient Cross-Linking Ability and Potent Cytotoxicity", J. Med. Chem., 44: 737-748 (2001)				
V	GREGSON, S.J. et al., "Effect of C2-exo Unsaturation on the Cytotoxicity and DNA-Binding Reactivity of Pyrrolo[2,1-c]1,4]benzodiazepines", Bioorganic & Medicinal Chemistry Letters, 10: 1845-1847 (2000)				

Examiner
Signature /Bruck Rifle/ (09/01/2006) Date
Considered 09/01/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Complete if Known Substitute for form 1449B/PTO Application Number 10/534,825 INFORMATION DISCLOSURE Filing Date May 27, 2005 First Named Inventor **David Thurston** STATEMENT BY APPLICANT Group Art Unit N/A (use as many sheets as necessary) **Examiner Name** N/A Sheet 琝 Attorney Docket Number 065435-9048 US00

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
xaminer Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
BK BK	GUIOTTO, A. et al., "Synthesis of novel C7-aryl substituted pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) via Pro-N10-troc protection and suzuki coupling," <i>Bioorganic & Medicinal Chemistry Letters</i> , 8, No. 21, 3017-3018 (1998)
	HARA et al., "DC 102, a new glycosidic pyrrolo(1,4)benzodiazepine antibiotic produced by streptomyces sp.", J. Antibiotics, 41, 702-704 (1988)
	HAUSKE, J. R. and DORFF, P., "Solid Phase CBZ Chloride Equivalent. A New Matrix Specific Linker", Tetrahedron Letters, 36, 10, 1589-1592 (1995)
	HOCART et al., "Highly potent cyclic disulfide antagonists of somatostatin," J. of Medicinal Chem., 42:11 (1999)
	HOCHLOWSKI, J. et al., "Abbeymycin, a new anthramycin-type antibiotic produced by a streptomycete," J. Antibiotics, 40, 145-148 (1987)
	HOLMES, C.P. and JONES, D.G., "Reagents for Combinatorial Organic Synthesis: Development of a New O-Nitrobenzyl Photolabile Linker for Solid Phase Synthesis", J. Org. Chem., 60, 2318-2319 (1995)
	HUBER, B. et al., "Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy," <i>Proc. Natl. Acad. Sci. USA</i> , 88, 8039-8043 (1991)
	HURLEY, L. and NEEDHAM-VANDEVANTER, D., "Covalent Binding of Antitumor Antibiotics in the Minor Groove of DNA. Mechanism of Action of CC-1065 and the Pyrrolo(1,4)benzodiazepines," Acc. Chem. Res., 19, 230-237 (1986)
	ITOH et al., "Sibanomicin, a new pyrrolo(1,4)benzodiazepine antitumor antibiotic produced by a micromonosporal sp." J. Antibiotics, 41, 1281-1284 (1988)
	JENKINS, T.C. et al., "Structure of a Covalent DNA Minor Groove Adduct with a Pyrrolobenzodiazepine Dimer: Evidence for Sequence-Specific Interstrand Cross-Linking," J. Med. Chem., 37, 4529-4537 (1994)
	JUNGHEIM, L.N. and SHEPHERD, T.A., "Design of Antitumor Prodrugs: Substrates for Antibody Targeted Enzymes," Am. Chem. Soc. Chem. Rev., 94, 1553-1566 (1994)
	KAMAL, A., et al., "An Efficient Synthesis of Pyrrolo[2,1-c][1,4] Benzodiazepine Antibiotics via Reductive Cyclization," Bioorg. Med. Chem. Ltrs, 7, No. 14, 1825-1828 (1997)
	KAMAL, A., et al., "Synthesis of Pyrrolo [2,1-c][1,4]-Benzodiazepene Antibiotics: Oxidation of Cyclic Secondary Amine with TPAP", <i>Tetrahedron</i> , v. 53, No. 9, 3223-3230 (1997)
	KAPOOR, T.M. et al., "Exploring the Specificity Pockets of Two Homologous SH3 Domains Using Structure-Based, Split-Pool Synthesis and Affinity-Based Selection," J. Am. Chem. Soc. 120:23-29 (1998)
Ψ	KATRITZKY et al., Heterocyclic Chemistry, John Wiley & Sons, Inc., 247-253 (1960)

Examiner	/Bruck Kifle/ (09/01/2006)	Date	/ /
Signature	/Bruck Rille/ (09/01/2000)	Considered	09/01/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

09/01/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for t	form 1449B/PTO				Complete if Known	
				Application Number	10/534,825	
INFOR	MATION	DISCL	OSURE	Filing Date	May 27, 2005	
STATE	EMENT B	Y APPL	ICANT	First Named Inventor	David Thurston	
		,		Group Art Unit	N/A	
	(use as many sheets as necessary)			Examiner Name	N/A	
Sheet	5	of	8	Attorney Docket Number	065435-9048 US00	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.					
BK	KENNEDY, J.C. and POTTIER, R.H., "Endogenous protoporphyrin IX, a clinical useful photosensitiser for photodynamic therapy," J. Photochem Photobiol, 14, 275-292 (1992)					
	KOHN, K., "Anthramycin," Antibiotics III, Springer-Verlag, NY, 3-11 (1975)					
	KONISHI, M. et al., "Chicamycin, a new antitumor antibiotic II. Structure determination of chicamycins A and B, J. Antibiotics, 37, 200-206 (1984)					
	KUNIMOTO et al., "Mazethramycin, a new member of anthramycin group antibiotics," J. Antibiotics, 33, 665-667 (1980)					
	KUNZ, H. and DOMBO, B., "Solid Phase Synthesis of Peptide and Glycopeptides on Polymeric Supports with Allylic Anchor Groups," Angew Chem. Int. Ed. Engl, 5, 711-713 (1988)					
	KUZMICH, S. et al., "Increased levels of glutathione S-transferase π transcript as a mechanism of resistance to ethacrynic acid," Journal of Biochemistry, 281, 219-224 (1992)					
	LANGLEY, D.R. and THURSTON, D.E., "A versatile and efficient synthesis of carbinolamine-containing pyrrolo[1,4]benzodiazepines via the cyclization of N-92-aminobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetals: total synthesis of prothracarcin," J. Org. Chem., 52, 91-97 (1987)					
	LEBER, J.D. et al., "A revised structure for sibiromycin," J. Am. Chem. Soc., 110, 2992-2993 (1988)					
	LEIMGRUBER, W. et al., "Isolation and characterization of anthramycin, a new antitumor antibiotic," J. Am. Chem. Soc., 87, 5791-5793 (1965)					
	LEIMGRUBER, W. et al., "The structure of anthramycin," J. Am. Chem. Soc., 87, 5793-5795 (1965)					
	LEIMGRUBER, W. et al., "Total synthesis of anthramycin," J. Am. Chem. Soc., 90, 5641-5643 (1968)					
	LESCRINIER, T. et al., "DNA-Binding Ligands from Peptide Libraries Containing Unnatural Amino Acids," Chem. Eur. J., 4, 3, 425-433 (1998)					
	LEWIS A.D. et al., "Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects," Carcinogenesis, 9, 1283-1287 (1988)					
	LOWN et al., "Molecular Mechanism of Binding of Pyrrolo(1,4)benzodiazepine antitumour agents to deoxyribonucleic acid – anthramycin and tomaymycin," Biochem. Pharmacol. (1979), 28 (13), 2017-2026; and Abstract No. 51709					
Ψ	MIZUSHIMA, S. and NAGATA, S., "pEF-BOS, a powerful mammalian expression vector," Nucl. Acids Res., 18, 5322 (1990)					
Examiner	(Proved Wifeles / 100 (01 (0000)) Date					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

/Bruck Kifle/ (09/01/2006)

Signature

considered. Include copy of this form with next communication to applicant.

Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

ubstitute for form 1449B/PTO					Complete if Known	
				Application Number	10/534,825	
INFORM	IATION	N DISCL	OSURE	Filing Date	May 27, 2005	
STATEMENT BY APPLICANT			ICANT	First Named Inventor	David Thurston	
				Group Art Unit	N/A	
(us	se as many she	ets as necessary)	Examiner Name	N/A	
Sheet 6 of 6			6	Attorney Docket Number	065435-9048 US00	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
BK	MONKS, A. et al., "Feasibility of High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines," Journal of National Cancer Institute, 83, 757-766 (1991)
	MORAN, E.J. et al., "Novel Biopolymers for Drug Discovery: Biopolymers", <i>Peptide Science</i> , John Wiley and Sons, 37: 213-19 (1995)
	MORGAN, R.A. and ANDERSON, W.F., "Human Gene Therapy," Annu. Rev. Biochem., 62, 191-217 (1993)
	MOSMANN, T., "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," J. Immunological Methods, 65, 55-63 (1983)
	MULLEN, D.G. and BARANY, G., "A New Fluoridolyzable Anchoring Linkage for Orthogonal Solid-Phase Peptide Synthesis: Design, Preparation, and Application of the N-(3 or 4)-[[4-(Hydroxymethyl) phenoxy]-tert-butylphenylsilyl]phenyl Pentanedioic Acid Monoamide (Pbs) Handle", J. Org. Chem., 53, 5240-5248 (1988)
	NAGASAKA, T. and KOSEKI, Y, "Stereoselective Synthesis of Tilivalline," <i>Journal of Organic Chemistry</i> , vol. 63, No. 20, 6797-6801 (1998)
	NAGASAKA, T. et al., "Stereoselective Synthesis of Tilivalline," Tetrahedron Letters, 30:14, 1871-1872 (1989)
	NICOLAOU, K.C. et al., "Designed Enediynes: A New Class of DNA-Cleaving Molecules with Potent and Selective Anticancer Activity," Science, 256, 1172-1178 (1992)
	NIELSON, P.E. et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide," Science, 254, 1497-1500 (1991)
	O'NEIL, I.A., et al., "The Synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines," Synlett, 75-78 (1997)
	O'NEIL, Chemical Abstract No. 171573p, "The synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines", Chemical Abstracts, vol. 126, No. 13, 618 (1997)
	O'NEIL, I.A. et al., "DPPE: A Convenient Replacement for Triphenylphosphine in the Staudinger and Mitsunobu Reactions", Tetrahedron Letters, vol. 39, No. 42, 7787-7790 (1998)
	PAIKOFF, S.J. et al., "The Solid Phase Synthesis of N-Alkylcarbamate Oligomers", <i>Tetrahedron Letters</i> , 37, No. 32: 5653-5656 (1996)
	PILLAI, V.N.R., "Photoremovable protecting groups in organic chemistry," Synthesis, 1-26 (1980)
V	RAM, Z. et al., "In Situ Retroviral-mediated Gene Transfer for the Treatment of Brain Tumors in Rats," Cancer Research, 53, 83-88 (1993)

Examiner		Date	
Signature	/Bruck Kifle/ (09/01/2006)	Considered	09/01/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for t	form 1449B/PTO				Complete if Known	
				Application Number	10/534,825	
INFOR	MATION	N DISCLO	DSURE	Filing Date	May 27, 2005	-
STATE	EMENT B	BY APPLI	CANT	First Named Inventor	David Thurston	
•				Group Art Unit	N/A	
	(use as many sheets as necessary)			Examiner Name	N/A	
Sheet	7	of	8	Attomey Docket Number	065435-9048 US00	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the anticle (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.					
вк	RAWAL, V.H. et al., "Photocyclization Strategy for the Synthesis of Antitumor Agent CC-1065: Synthesis of Dideoxy PDE-I and PDE-II. Synthesis of Thiophene and Furan Analogues of Dideoxy PDE-I and PDE-II," J. Org. Chem., 52, 19-28 (1987)					
	REGULA, J. et al., "Photosensitisation and photodynamic therapy of oesophagael, duodenal and colorectal tumours using 5-aminoleavulic acid induced photoporphyrin IX-a pilot study," Gut, 36, 67-75 (1995)					
	SAGNOU, M.J. et al., "Design and Synthesis of Novel Pyrrolobenzodiazepine (PDB) Prodrugs for ADEPT and GDEPT," Bioorganic & Medicinal Chemistry Letters, 10, 2083-2086 (2000)					
	SAHA, A.K. et al., "Diisopropylsilyl-Linked Oligonucleotide Analogs: Solid-Phase Synthesis and Physiocochemical Properties," J. Org. Chem., 58, 7827-7831 (1993)					
	SATYAM, A. et al., "Design, Synthesis, and Evaluation of Latent Alkylating Agents Activated by Glutathione S-Transferase," J. Med. Chem., 39, 1736-1747 (1996)					
	SHIMIZU, K et al., "Prothracarcin, a Novel Antitumor Antibiotic," J. Antibiotics, 35, 972-978 (1982)					
	SIMON, R.J. et al., "Peptoids: A Modular Approach to Drug Discovery", <i>Proc. Natl. Acad. Sci.</i> USA,89:9367-937 (1992) SOTH, M.J. and NOWICK, J.S., "Unnatural oligomers and unnatural oligomer libraries", <i>Curr. Opin. Chem. Biol.</i> , 1:120-129 (1997)					
	STAR, W.M., "Light delivery and light dosimetry for photodynamic therapy," Lasers in Medical Science, 5:107-113 (1990)					
	SUGGS, J.W. et al., "Synthesis and structure of anthramycin analogs via hydride reduction of dilactams," Tetrahedron Letters, 26, No. 40, 4871-4874 (1985)					
	TAKEUCHI, T. et al., "Neothramycins A and B, New Antitumor Antibiotics," J. Antibiotics, 29, 93-96 (1976)					
	TEW, K.D. and CLAPPER, M.L., "Glutathione-S-transferase and anti-cancer drug resistance," <i>Mechanism of Drug Resistance in Neoplastic Cells</i> , Woolley, P.V. and Tew, K.D., Eds, Academic Press: Sand Diego, CA 141-159 (1988)					
	THURSTON, D.E. and THOMPSON, A.S., "The molecular recognition of DNA," Chem. Brit., 26, 767-772 (1990)					
	THURSTON, D.E. and BOSE, D.S., "Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines," Chem. Rev., 94:433-465 (1994)					
	THURSTON, D. E., "Advances in the study of Pyrrolo[2,1-c][1,4] benzodiazepine (PBD) Antitumour Antibiotics" Molecular Aspects of Anticancer Drug-DNA Interaction, Neidle, S. and Waring, M.J., Eds.; Macmillan Press Ltd, 1:54-88 (1993)					
Examiner Signature	/Bruck Kifle/ (09/01/2006) Date Considered 09/01/2006					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO					Complete if Known	
3033				Application Number	10/534,825	
INFORMATION DISCLOSURE			OSURE	Filing Date	May 27, 2005	
STATE	STATEMENT BY APPLICANT			First Named Inventor	David Thurston	
				Group Art Unit	N/A	
(use as many sheets as necessary)				Examiner Name	N/A	
Sheet	8	of	g	Attorney Docket Number	065435-9048 US00	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.				
BK	THURSTON, D.E. et al., "Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c][1,4]benzodiazepines", Journal of Medicinal Chemistry, 42:1951-1964 (1999)				
	THURSTON, D.E. et al., "Synthesis of Sequence-selective C8-linked Pyrrolo [2,1-c][1,4] Benzodiazepine DNA Interstrand Cross-linking Agent," J. Org. Chem., 61:8141-8147 (1996)				
	THURSTON, D.E. et al., "Synthesis of a novel GC-specific covalent-binding DNA affinity-cleavage agent based on pyrrolobenzodiazepines (PBDs)," Chemical Communications, 563-565 (1996)				
	TSUNAKAWA, M. et al., "Porothramycin, a new antibiotic of the anthramycin group: Production, isolation, structure and biological activity," J. Antibiotics, 41:1366-1373 (1988)				
	UMEZAWA, H. et al., Chemical Abstract No. 4427a, "Mazethramycins" Chemical Abstracts, vol. 90, No. 1, 428 (1979)				
	UMEZAWA, H. et al., "Mazethramycins," SciFinder Scholar, 2-3 (2002)				
	WILSON, S.C. et al., "Design and Synthesis of a Novel Epoxide-Containing Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) via a New Cyclization Procedure," <i>Tetrahedron Letters</i> , 36, No. 35, 6333-6336 (1995)				
	WILSON, S.C. et al., "Design, Synthesis, and Evaluation of a Novel Sequence-Selective Epoxide-Containing DNA Cross-Linking Agent Based on the Pyrrolo[2,1-c][1,4]benzodiazepine System", J. Med. Chem. 42:4028-4041 (1999)				
	ZUCKERMAN, R.N. et al., "Discovery of Nanomolecular Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted) glycine Peptoid Library", J. Med. Chem., 37:2678-2685 (1994)				
V	Dictionary of Science and Technology, Professor P.M.B. Walker ed. Larousse plc., pp. 63, 457, 523 (1995)				

Q:\CLIENT\065435\9048\B0620172.1

Examiner	/Bruck Kifle/ (09/01/2006)	Date	09/01/2006
Signature	/Bruck kille/ (05/01/2000)	Considered	09/01/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449/PTO	.	mplete if Known
1011	INFORMATION DISCLOSUR STATEMENT BY APPLICAN	Application Number	10/534,825
1	ACT A TENENTE DIV A DDI 10 A N	Filing Date	October 20, 2005
	STATEMENT BY APPLICAN	First named Inventor	David Edwin Thurston
APR 26	2006	Group Art Unit	1614
	(use as many sheets as necessary)	Examiner name	Unknown
	Sheet 1 of 2	Attorney Docket Number	065435-9048-US00
& THORN	wet/		
CADE		U.S. Patent Documents	
Examiner Initials	U.S. Patent Document Numb	er Name of Patentee or Applicant of C Document	Date of Publication of Cited Document
BK	6,660,856	Wang	12/9/2003

				FOREIGN PATENT DOCUME	NTS		
Exam Initi		Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
В	SK .	EP	1193270	Spirogen Ltd.	4/3/2002		
		GB	2053894	The Green Cross Corporation	2/11/1981		
		wo	88/04659	The Upjohn Company	6/30/1988		
		wo	91/16324	The Upjohn Company	10/31/1991		
		wo	96/23497	Synphar Laboratories, Inc.	8/8/1996		
		wo	97/07097	Auckland Division Cancer Society of New Zealand Inc.	2/27/1997		
		wo	98/11101	Auckland Division Cancer Society of New Zealand Inc.	3/19/1998		
		wo	98/12197	Kyorin Pharmaceuticals Co., Ltd. et al.	3/26/1998	N	Y
		wo	99/29642	The Scripps Research Institute	6/17/1999		
	V	wo	99/46244	Novo Nordisk A/S et al.	9/16/1999		

Examiner Signature	/Bruck Kifle/ (09/01/2006)	Date Considered	09/01/2006
L			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	Substitute for form 1449/PTO			Complete if Known			
	INTEN	RMATION DISCLOSU	Applicati	Application Number 10/534,825			
			Filing Do	Filing Date October 20			
	STAT	EMENT BY APPLICA	First dam	ed Inventor	David Ed	win Thurston	
			Group Art	Unit	1614		
	(บ	se as many sheets as necessary)	Examiner		Unknown		
		Sheet 2of 2	Attorney I	Docket Number	065435-9	048-US00	
 			U.S. Patent Documents			-	
		I	OREIGN PATENT DOC	UMENTS			
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Docume		Publication of Cited Document	Translation	English Abstract
BK	wo	00/12508	The University of Portsmo Higher Education Corp		3/9/2000		
	wo	00/12509	The University of Portsmo Higher Education Corp		3/9/2000		
	wo	00/64864	Cancer Campaign Resear Technology Ltd.	rch 1	1/2/2000		
	wo	2004/043963	Spirogen Ltd.		5/27/2004		
. [wo	2005/023814	Spirogen Ltd.	3	3/17/2005		
	wo	2005/040170	Government of the U.S.A al.	. et	5/6/2005		
- W	wo	2005/085251	Spirogen Ltd.	9	9/15/2005		

Examiner Signature /Bruck Kifle/ (09/01/2006)	Date Considered	09/01/2006
---	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

te for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet I of

Complete if Known				
Application Number	10/534,825			
Filing Date	October 20, 2005			
First Named Inventor	David Edwin Thurston			
Group Art Unit	1614			
Examiner Name	Unknown			
Attorney Docket Number	065435-9048-US00			

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
BK	ADAMS et al., "Molecular modelling of a sequence-specific DNA-binding agent based on the pyrrolo[2,1-c][1,4]benzodiazepines," Pharm. Pharmacol. Commun. (1999) 5:555-560
	BARALDI, P.G. et al., "[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid inhibits DNA binding to transcription factor Sp1," Nucleotides and Nucleic Acids (2000) 19(8):1219-1229
	BERGE et al., "Pharmaceutical Salts," J. Pharm. Sci. (1977) 66:1-19
	BORGATTI, M. et al., "Inhibition of NF-kB/DNA interactions and HIV-1 LTR directed transcription by hybrid molecules containing pyrrolo [2,1-c][1,4] benzodiazepine (PBD) and oligopyrrole carriers," Drug Development Research (2003) 60(3):173-185
	BOSE, D.S. et al., "Effect of linker length on DNA-binding affinity, cross-linking efficiency and cytotoxicity of C8 linked pyrrolobenzodiazepine dimers," J. Chem. Soc. Chem. Commun. (1992) 20:1518-1520
	CHEN, Z. et al., "A novel approach to the synthesis of cytotoxic C2-C3 unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) with conjugated acrylyl C2-substituents," Biorg. Med. Chem. Lett. (2004) 14:1547-1549
	COOPER, N. et al., "Synthesis of novel PBDs as anti-tumour agents," Chem. Commun. (2002) 16:1764-1765
	DE GROOT, FMH et al., "Synthesis and biological evaluation of 2'-carbamate-linked 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin," J. Med. Chem. (2000) 43(16):3093-3102
$\overline{\downarrow}$	DE GROOT, FMH et al., "Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin," Biorg. Med. Chem. Lett. (2002) 12(17):2371-2376
<u> </u>	

Examiner	/P	Date	09/01/2006
Signature	/Bruck Kifle/ (09/01/2006)	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO					Complete if Known	
				Application Number	10/534,825	
INFORMATION DISCLOSURE			OSURE	Filing Date	October 20, 2005	
STATEMENT BY APPLICANT			ICANT	First Named Inventor	David Edwin Thurston	
				Group Art Unit	1614	
(use as many sheets as necessary))	Examiner Name	Unknown	
Sheet	2	of	5	Attorney Docket Number	065435-9048-US00	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
DUBOWCHIK, G.M. et al., "Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin," Biorg. Med. Chem. Lett. (1998) 8:3341-3346
DUBOWCHIK, G.M. et al., "Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), Mitomycin C and Doxorubicin," Biorg. Med. Chem. Lett. (1998) 8:3347-3352
DUBOWCHIK and WALKER, "Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs," Pharmacology and Therapeutics (1999) 83:67-123
GARSKY et al., "The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy," J. Med. Chem. (2001) 44:4216-4224
GREGSON, S.J. et al., "Effect of C2/C3-endo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo-[2,1-c][1,4]-benzodiazepines," Bioorg. Med. Chem. Lett. (2000) 10(16):1849-1851
GREGSON, S.J. et al., "Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers," J. Med. Chem. (2004) 1161-1174
GREGSON, S.J. et al., "Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer," Biorg. Med. Chem. Lett. (2001) 11:2859-2862
GREGSON, S.J. et al., "Synthesis of the first examples of A-C8/C-C2 amide-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers," Biorg. Med. Chem. Lett. (2003) 13:2277-2280
HAMBURGER, A.W. et al., "Primary bioassay of human tumor stem cells," Science (1977) 197:461-643

			
Examiner		Date	
Daumunci	/Bruck Kifle/ (09/01/2006)	Dute	09/01/2006
Signature	/Bruck kille/ (03/01/2000)	Considered	03/01/2000
Signature		Constuered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO					Complete if Known	
				Application Number	10/534,825	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			OSURE	Filing Date	October 20, 2005	
			ICANT	First Named Inventor	David Edwin Thurston	
				Group Art Unit	1614	
(use as many sheets as necessary)		Examiner Name	Unknown			
Sheet	3	of	5	Attorney Docket Number	065435-9048-US00	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.					
ВК	JAKOBSEN et al., "Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells," J. Med. Chem. (2001) 44:4696-4703					
	KAMAL et al., "Synthesis and DNA-binding affinity of A-C8/C-C2 alkoxyamido-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers" Biorg. Med. Chem. Lett. (2003) 13(22):3955-3958					
	KAMAL, et al., "Synthesis of pyrrolo[2,1-c][1,4]benzodiazepines via reductive cyclization of w-azido carbonyl compounds by TMSI: an efficient preparation of antibiotic DC-81 and its dimers," Biorg. Med. Chem. Lett. (2000) 10:2311-2313					
	KANEKO, T. et al., "Bicyclic and tricyclic analogues of anthramycin," J. Med. Chem. (1985) 28:388-392					
	KANG, GD. et al., "Synthesis of a novel C2-aryl substituted 1,2-unsaturated pyrrolobenzodiazepine," Chem. Commun. (2003) 1688-1689					
	KUMAR, R. et al., "Synthesis and antitumor cytotoxicity evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine imidazole containing polyamide conjugates," Oncology Research (2003) 13(4):221-223					
	KUMAR, R. et al., "Design and synthesis of novel pyrrolo[2,1-c][1,4]benzodiazepine - imidazole containing polyamide conjugates," Heterocyclic Communications (2002) 81(1):19-26					
	KUMAR, R. et al., "Design, synthesis and in vitro cytotoxicity studies of novel pyrrolo [2,1][1,4]benzodiazepine-glycosylated pyrrole and imidazole polyamide conjugates," Org. Biomol. Chem. (2003) 1(19):3327-3342					
\downarrow	LANGLOIS, N. et al., "Synthesis and cytotoxicity on sensitive and doxorubicin-resistant cell lines of new pyrrolo[2,1-c][1,4]benzodiazepines related to anthramycin," J. Med. Chem. (2001) 44:3754-3757					

Examiner		Date	
Signature	/Bruck Kifle/ (09/01/2006)	Considered	09/01/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO					Complete if Known	
				Application Number	10/534,825	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			OSURE	Filing Date	October 20, 2005	
			ICANT	First Named Inventor	David Edwin Thurston	
				Group Art Unit	1614	
			•	Examiner Name	Unknown	
Sheet	4	of	5	Attorney Docket Number	065435-9048-US00	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
ВК	LIPSHUTZ, B.H. et al., "Pd(II)_Catalyzed Acetal/Ehtal Hydrolysis/Exchange Reactions," Tetrahedron Lett. (1985) 26(6):705-708
	MHAKA et al., "A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer," Biorg. Med. Chem. Lett. (2002) 12(17:2459-2461
	MISCHIATI, C. et al., "Binding of hybrid molecules containing pyrrolo [2,1-c][1,4]benzodiazepine (PBD) and oligopyrrole carriers to the human immunodeficiency type 1 virus TAR-RNA," Biochem. Pharmacol. (2004) 67(3):401-410
	MORI, M. et al., "Total syntheses of prothracarcin and tomaymycin by use of palladium catalyzed carbonylation," Tetrahedron (1986) 42(14):3793-3806
	MOUNTZOURIS, J.A. et al., "Comparison of a DSB-120 DNA interstrand cross-linked adduct with the corresponding bis-Tomamycin adduct," J. Med. Chem. (1994) 37:3132-3140
	NICULESCU-DUVAZ, D. et al., "Self-immolative nitrogen mustard prodrugs for suicide gene therapy," J. Med. Chem. (1998) 41(26):5297-5309
	REDDY et al., "Design, synthesis and in vitro cytotoxicity studies of novel pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-polyamide conjugates and 2,2'-PBD dimers," Anti-Cancer Drug Design (2000) 15(3):225-228
	SMELLIE, M. et al., "Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents," Br. J. Cancer (1994) 70:48-53
V	SMELLIE, M. et al., "Sequence selective recognition of duplex DNA through covalent interstrand cross-linking," Biochem. (2003) 42:8232-8239
	

			
Examiner		Date	1
DAMILLIE	/Bruck Kifle/ (09/01/2006)	Date	09/01/2006
Ciamatoria	/Bluck Kille/ (09/01/2006)	0	1 05/01/2006 [
Signature		Considered	j

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO					Complete if Known	
	Substitute for 15th 1 to 15th			Application Number	10/534,825	
INFOR	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	October 20, 2005	
STATE				First Named Inventor	David Edwin Thurston	
				Group Art Unit	1614	
(use as many sheets as necessary)		Examiner Name	Unknown			
Sheet	5	of	5	Attorney Docket Number	065435-9048-US00	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
BK	THURSTON, D.E., "Nucleic acid targeting: therapeutic strategies for the 21st century," Brit. J. Cancer (1999) 80(1):65-85
	TIBERGHIEN, A.C. et al., "Application of the stille coupling reaction to the synthesis of C2-substituted endo-exo unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)," Biorg. Med. Chem. Lett. (2004) 14:5041-5044
-	WELLS, G. et al., "Pyrrolobenzodiazepine-polyamide libraries: synthesis and DNA binding selectivity," Proc. Am. Assoc. Canc. Res. (2003) 44:85-86, #452
	WERMUTH et al., "Molecular Variations Based on Isosteric Replacements," The Practice of Medicinal Chemistry, Chapter 13 (1996) 203-237
\downarrow	WILLIAMS, M.A. et al., "Synthesis of conformationally constrained DTPA analogues. Incorporation of the ethylenediamine units as aminopyrrolidines," J. Org. Chem. (1994) 59(13):3616-3625

Examiner		Date	00/01/2006
Signature	/Bruck Kifle/ (09/01/2006)	Considered	09/01/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.